CureLab, a Boston, MA-based biotechnology company advancing an anti-cancer and anti-inflammatory drug, raised $3M in funding.
The round was led by Dr. John Ballantyne, the co-founder and former chief scientific officer of Aldevron, a leading manufacturer of plasmids and other biologicals.
Led by CEO Dr. Alexander Shneider, CureLab is dedicated to advancing new and safer therapeutics for solid tumors and other oncology and inflammatory indications. It operates two sister companies, CureLab Oncology and CureLab Veterinary. The first is a pre-IPO, clinical-stage immuno-oncology biotech company. The second is dedicated to bringing advanced therapies to treat cancer and inflammatory diseases to support better pet health and longevity.
Both CureLab Oncology and CureLab Veterinary are developing therapies that employ plasmids (circular DNA encoding a gene called p62/SQSTM1). CureLab Oncology is applying the p62 plasmid to treat human cancers. Following clinical data presented at the European Society for Medical Oncology Congress in Paris, and the considerable ongoing progress of the company’s clinical studies, the funds will enable CureLab Oncology to ramp up toward FDA-monitored clinical trials for triple-negative breast cancer and platinum-resistant ovarian cancer in 2023.
FinSMEs
02/03/2023